Free Hemoglobin

Hemoglobin normally carries oxygen inside red blood cells. When those cells break open inside blood vessels, hemoglobin enters the plasma. Plasma is the liquid part of blood. This test measures the concentration of hemoglobin outside red cells, but damage to cells during collection can produce the same finding.

Plasma free hemoglobin has an established role in investigating suspected red cell destruction and monitoring complications of mechanical heart support and transfusions. Its use as a predictor of kidney injury or death in severe illness is still being studied. Those hospital findings haven't established a benefit from screening healthy people.

What Happens to Released Hemoglobin

The body normally removes aging red cells through specialized cells in the spleen and liver. Red cell destruction is called hemolysis. When it happens inside blood vessels, it's called intravascular hemolysis. Destruction within the spleen or liver is called extravascular hemolysis, and it may occur without a substantial rise in plasma free hemoglobin.

Haptoglobin binds hemoglobin released into blood and helps carry it to cells that clear it. The concentration left in plasma depends on both release and clearance, so it isn't a direct count of how many red cells are being destroyed. In laboratory terminology, 'free' generally refers to hemoglobin outside red cells; some measurements include hemoglobin already bound to haptoglobin.

Outside red cells, hemoglobin reacts readily with nitric oxide. Nitric oxide helps blood vessels relax and limits platelet activation. Human studies in sickle cell disease have connected circulating cell-free hemoglobin with increased nitric oxide consumption and impaired blood vessel responses.

Hemoglobin can also release heme. Heme is its iron-containing component. Animal and cell experiments show that reactions involving hemoglobin and heme can damage cell membranes and kidney tubules. When circulating binding systems are overwhelmed, unbound hemoglobin can pass through the kidneys' filters and expose those tubules to injury.

Kidney Injury

Some of the clearest human evidence comes from heart and major aortic surgery. Plasma free hemoglobin rises during procedures that circulate blood through a machine, and greater exposure has been associated with urinary signs of kidney tubule injury and subsequent acute kidney injury. These studies support a link, though low blood pressure, inflammation, and other surgical complications can contribute to kidney damage too. Not every surgical cohort has reproduced it: a study of 154 cardiac surgery patients found no significant relationship between free hemoglobin or haptoglobin and kidney injury after the operation.

A conference meta-analysis of cardiac surgery studies found that depleted haptoglobin was associated with higher odds of acute kidney injury. That estimate concerns the companion protein that binds released hemoglobin, not the plasma free hemoglobin measurement itself, and it has so far appeared only as an abstract.

ECMO circulates blood outside the body to provide oxygen or support the heart. In a study of 273 adults with severe lung failure, those in the study's highest plasma free hemoglobin group before ECMO began had about five times the odds of severe kidney injury already present at that point, compared with those in the lowest group. Higher haptoglobin was associated with less kidney injury. The timing matters: this study did not show that ECMO caused those initial findings or that giving haptoglobin would prevent them.

The association also appears in severe malaria. Among 107 adults, those who already had acute kidney injury at enrollment had plasma free hemoglobin concentrations about 70% higher than those without it. Higher concentrations were also associated with worsening kidney function over the next three days.

These findings make kidney function relevant when intravascular hemolysis is confirmed. Kidney injury is usually judged first by creatinine and urine output. They don't provide a formula for translating an isolated outpatient result into your personal risk of kidney failure.

Survival in Severe Illness

Several intensive care studies have associated higher plasma free hemoglobin with mortality, including after adjustment for measured illness severity. The strength of the association varies with the population, timing, and measurement method.

In another study of 442 adults receiving ECMO for severe lung failure, higher average concentrations and more persistent elevations were associated with higher intensive care mortality. A trauma study also found that concentrations measured within 30 minutes of emergency department arrival were associated with later complications. That was time from arrival, not necessarily time from injury.

These are observational findings in people who were already seriously ill. They don't establish how much of the excess risk came from hemoglobin itself, and they can't be used to predict lifespan in someone who is otherwise well.

Inherited and Immune Hemolytic Disorders

Sickle cell disease, thalassemia, and immune hemolytic disorders can destroy red cells through different combinations of intravascular and extravascular hemolysis. Plasma free hemoglobin reflects the circulating component. It can therefore add useful information without capturing the full severity of the disease.

In sickle cell disease, higher plasma free hemoglobin has been associated with poorer artery dilation in response to increased blood flow. This supports its connection to blood vessel dysfunction, but an individual result doesn't diagnose pulmonary hypertension or measure existing artery damage.

Research on haptoglobin genetics provides related evidence about the clearance system. Two cohorts of children with sickle cell anemia linked one haptoglobin genotype to more severe pain episodes. That study examined inherited differences in haptoglobin, so it does not establish how a particular plasma free hemoglobin result predicts pain.

Pregnancy Research

Preeclampsia involves high blood pressure during pregnancy and can damage organs. Studies have found increased cell-free fetal hemoglobin and changes in hemoglobin-binding proteins in affected pregnancies. Fetal hemoglobin is a specific form of the protein, and measuring it separately is different from this general plasma free hemoglobin test. These findings remain research observations and don't establish this test as a way to screen for or diagnose preeclampsia.

How It Differs From Your Blood Count

A complete blood count measures total hemoglobin in whole blood. Almost all of that hemoglobin is inside red cells, and the result helps establish whether you have anemia. Plasma free hemoglobin measures the much smaller amount outside the cells. The measurements can move independently, including when your bone marrow replaces destroyed cells fast enough to prevent anemia.

Plasma free hemoglobin also doesn't identify the cause of hemolysis. An immune reaction, an inherited red cell disorder, an infection, and mechanical damage can produce similar results. In a severe sepsis study, most measurement methods did not distinguish sepsis from the changes seen after surgery.

When Results Can Be Misleading

Red cells can break during collection or after blood enters the tube. The resulting hemoglobin is then measured even though it never circulated freely in your body. An unexpected result must be interpreted with the sample's condition and other findings.

• Collection and handling: a traumatic draw, forceful handling, or delayed separation of plasma from cells can falsely increase the result.
• Specimen differences: serum is produced after blood clots, which can release additional hemoglobin. Serum research values should not be treated as interchangeable with this plasma measurement.
• Method differences: laboratories use different ways to quantify plasma hemoglobin. Bilirubin and fat in the sample can interfere with some methods, and an automated hemolysis index is not automatically equivalent to a dedicated free hemoglobin measurement.
• Recent clinical events: transfusion, major injury, or surgery using a heart-lung machine can cause real short-term changes. Their duration varies, so the result may describe that event rather than your usual state.
• Companion markers: inflammation and corticosteroids can raise haptoglobin and mask its depletion. Liver disease or inherited low haptoglobin can lower it without active hemolysis. LDH can rise from damage to other tissues or from red cells breaking in the sample.

What a Trend Can Show

Repeated measurements can help show whether intravascular hemolysis is continuing in a particular clinical setting. In an exploratory analysis of heart surgery data, the change from the preoperative concentration to the end of bypass was associated with acute kidney injury. That finding doesn't establish a general outpatient monitoring schedule or make a personal baseline a substitute for the rest of the evaluation.

A falling concentration can reflect less release, faster clearance, or a change in sampling conditions. The trend is most useful when it agrees with symptoms, the blood count, other hemolysis markers, and kidney function.